Product Profile

Our lead drug candidate is L-CsA, a new liposomal formulation of Cyclosporine A developed for inhaled drug delivery into the lungs. For precise pulmonary drug targeting we use a high-performance eFlow® Technology nebulizer (PARI Pharma GmbH) specially customized for L-CsA and equipped with digital adherence monitoring capabilities.

This proprietary drug device combination provides for the first time a safe and well tolerated inhalation of immunosuppressive medication along with effective pulmonary dosing of L-CsA.

L-CsA, Liposomal Cyclosporine A Formulation
L-CsA, Liposomal Cyclosporine A Formulation
eFlow®, aerosol nebulizer “L-CsA version”
eFlow®, aerosol nebulizer “L-CsA version”